Health Professional Radio - Podcast

Dr. Rahul Aras, CEO of Iterion Therapeutics, a clinical stage biotechnology company developing novel cancer therapeutics discusses the company's lead product, Tegavivint, a unique nuclear β-catenin inhibitor, which is currently advancing to a Phase 2 clinical trial in patients with progressive desmoid tumors. The company will also pursue additional clinical programs in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers this year and in 2021.